This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: The Jackson Laboratory, Albert Einstein College of Medicine. Active years: 2012-2023.
Location History:
- Ellsworth, ME (US) (2012)
- Bar Harbor, ME (US) (2023)
Company Filing History:
2 out of 96 
1 out of 513 
Years Active: 2012-2023
Title: David V Serreze: Innovator in Diabetes Research
Introduction
David V Serreze is a prominent inventor based in Ellsworth, ME (US). He has made significant contributions to the field of diabetes research, particularly in the development of therapies for type 1 diabetes. With a total of 2 patents, his work has the potential to impact the lives of many individuals affected by this condition.
Latest Patents
One of his latest patents is titled "Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development." This patent relates to genetically modified non-obese diabetic (NOD) mice that are deficient in murine class I MHC molecules, class II molecules, or both. These MHC knockout transgenic mice are valuable for developing therapies aimed at treating diabetes. Another significant patent is "Antigens targeted by pathogenic AI4 T cells in type 1 diabetes and uses thereof." This patent provides oligopeptide antigens to AI4-like T cells and mouse proteins that comprise those antigens. The methods described in this patent offer innovative approaches for treating mammals at risk for or suffering from type 1 diabetes.
Career Highlights
Throughout his career, David V Serreze has worked with esteemed institutions such as The Jackson Laboratory and Albert Einstein College of Medicine. His research has focused on understanding the mechanisms of type 1 diabetes and developing effective therapies.
Collaborations
David has collaborated with notable colleagues, including Teresa P DiLorenzo and Scott M Lieberman. These partnerships have furthered his research and contributed to advancements in diabetes treatment.
Conclusion
David V Serreze is a dedicated inventor whose work in diabetes research is paving the way for new therapeutic options. His innovative patents and collaborations highlight his commitment to improving the lives of those affected by type 1 diabetes.